Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Alabama: - Infirmary Cancer Care — Mobile, Alabama
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Alabama: - University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Alabama: - GSK Investigational Site — Mobile, Alabama
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 3 Recruiting Industry
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multip…
Sponsor: Takeda
NCT ID: NCT06980480
Sites in Alabama: - Infirmary Health - Diagnostic & Medical Clinic (DMC) — Mobile, Alabama
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Alabama: - University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Alabama: - Research Site — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Alabama: - University of Alabama At Birmingham Hospital — Birmingham, Alabama
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Sponsor: ModernaTX, Inc.
NCT ID: NCT07116616
Sites in Alabama: - University of Alabama at Birmingham Hospital — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05231629
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06974786
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05372354
Sites in Alabama: - UAB Comprehensive Cancer Center — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Sponsor: Celgene
NCT ID: NCT06988488
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma (coho…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT04991103
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple…
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06121843
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to as…
Sponsor: Caribou Biosciences, Inc.
NCT ID: NCT05722418
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06153251
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Academic/Other
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Sponsor: Susan Bal
NCT ID: NCT07333261
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Academic/Other
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal…
Sponsor: Tufts Medical Center
NCT ID: NCT06365060
Sites in Alabama: - University of Alabama Hospital — Birmingham, Alabama
Recruiting Academic/Other
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients age…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05556928
Sites in Alabama: - Kirklin Clinic of UAB Hospital — Birmingham, Alabama
NA Recruiting Academic/Other
This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or an attention control group before their …
Sponsor: Noha Mohamed Sharafeldin
NCT ID: NCT05642884
Sites in Alabama: - Kirklin Clinic of UAB Hospital — Birmingham, Alabama